We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+9.63%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$59.8B
AUM Growth
+$5.07B
(+9.3%)
Cap. Flow
+$518M
Cap. Flow
% of AUM
0.87%
Top 10 Holdings %
Top 10 Hldgs %
18.08%
Holding
2,992
New
38
Increased
2,358
Reduced
537
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$68M |
| 2 |
Truist Financial
TFC
|
+$55.9M |
| 3 |
ServiceNow
NOW
|
+$33.3M |
| 4 |
Uber
UBER
|
+$21.4M |
| 5 |
Las Vegas Sands
LVS
|
+$15.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$119M |
| 2 |
STI
SunTrust Banks, Inc.
STI
|
+$55.9M |
| 3 |
Apple
AAPL
|
+$48.3M |
| 4 |
iShares TIPS Bond ETF
TIP
|
+$22M |
| 5 |
VIAB
Viacom Inc. Class B
VIAB
|
+$16.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Financials | 15.53% |
| 3 | Healthcare | 13.38% |
| 4 | Consumer Discretionary | 10.07% |
| 5 | Industrials | 9.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2501
Ares Capital
ARCC
$13.9B
| $364K | ﹤0.01% |
19,523
+39
| +0.2% | +$724 |
|
|
PFBI
2502
DELISTED
Premier Financial Bancorp
PFBI
| $364K | ﹤0.01% |
20,054
+3
| +0% | +$53 |
|
|
SWTX
2503
DELISTED
SpringWorks Therapeutics
SWTX
| $363K | ﹤0.01% |
+9,426
| New | +$221K |
|
|
VRAY
2504
DELISTED
ViewRay, Inc.
VRAY
| $363K | ﹤0.01% |
85,998
+757
| +0.9% | +$2.45K |
|
2505
Ceco Environmental
CECO
$4.04B
| $362K | ﹤0.01% |
47,318
+306
| +0.7% | +$2.29K |
|
2506
First Internet Bancorp
INBK
$256M
| $362K | ﹤0.01% |
15,259
+26
| +0.2% | +$591 |
|
2507
Puma Biotechnology
PBYI
$407M
| $362K | ﹤0.01% |
41,422
+893
| +2% | +$7.39K |
|
|
FPI
2508
Farmland Partners
FPI
$431M
| $360K | ﹤0.01% |
53,119
+2,739
| +5% | +$18K |
|
|
AT
2509
DELISTED
Atlantic Power Corporation
AT
| $360K | ﹤0.01% |
154,459
-5,638
| -4% | -$13.3K |
|
|
TPCO
2510
DELISTED
Tribune Publishing Company Common Stock
TPCO
| $359K | ﹤0.01% |
27,302
+290
| +1% | +$3.05K |
|
2511
MediciNova
MNOV
$65.5M
| $357K | ﹤0.01% |
52,994
+280
| +0.5% | +$2.11K |
|
|
ZAGG
2512
DELISTED
ZAGG Inc Common Stock (Delaware)
ZAGG
| $357K | ﹤0.01% |
43,963
+354
| +0.8% | +$2.63K |
|
2513
Norwood Financial Corp
NWFL
$371M
| $356K | ﹤0.01% |
9,164
-34
| -0.4% | -$1.16K |
|
2514
Mitek Systems
MITK
$774M
| $354K | ﹤0.01% |
46,249
+372
| +0.8% | +$3.14K |
|
2515
XBiotech
XBIT
$68.9M
| $354K | ﹤0.01% |
18,940
+5,269
| +39% | +$67.8K |
|
2516
Immersion
IMMR
$255M
| $352K | ﹤0.01% |
47,361
+531
| +1% | +$3.98K |
|
2517
SI-BONE Inc
SIBN
$800M
| $352K | ﹤0.01% |
16,369
+110
| +0.7% | +$1.97K |
|
|
CVLY
2518
DELISTED
Codorus Valley Bancorp Inc
CVLY
| $351K | ﹤0.01% |
15,246
-79
| -0.5% | -$1.74K |
|
2519
iShares Russell Mid-Cap Growth ETF
IWP
$20.4B
| $350K | ﹤0.01% |
4,590
+800
| +21% | +$58.6K |
|
2520
IES Holdings
IESC
$15.6B
| $349K | ﹤0.01% |
13,582
+113
| +0.8% | +$2.44K |
|
2521
MVB Financial
MVBF
$395M
| $349K | ﹤0.01% |
14,014
-32
| -0.2% | -$678 |
|
2522
BayCom
BCML
$335M
| $348K | ﹤0.01% |
15,306
-42
| -0.3% | -$928 |
|
|
LBC
2523
DELISTED
Luther Burbank Corporation Common Stock
LBC
| $347K | ﹤0.01% |
30,119
-56
| -0.2% | -$637 |
|
|
ACOR
2524
DELISTED
Acorda Therapeutics
ACOR
| $347K | ﹤0.01% |
1,416
+155
| +12% | +$39.1K |
|
2525
Shore Bancshares
SHBI
$814M
| $344K | ﹤0.01% |
19,837
-49
| -0.2% | -$801 |
|
Similar funds
VAM
RhumbLine Advisers's Q4 2019 Portfolio in Review
As of Q4 2019, RhumbLine Advisers held 2,992 positions worth $59.8B, up 9.3% from $54.7B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Trading was light in Q4 2019: portfolio turnover was 2.7%. RhumbLine Advisers opened 38 new positions and exited 43, leaving the 2,992-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q4 2019 buy was Envista: 126,664 shares worth $3.75M.
- RhumbLine Advisers added most to Bristol-Myers Squibb in Q4 2019, an estimated $68M increase.
- RhumbLine Advisers's biggest Q4 2019 reduction was Apple, cutting an estimated $48.3M.
- RhumbLine Advisers fully exited Celgene Corp in Q4 2019, selling an estimated $119M.
- RhumbLine Advisers's ten largest holdings make up 18% of its $59.8B portfolio in Q4 2019.
- RhumbLine Advisers opened 38 new positions and closed 43 in Q4 2019.
- RhumbLine Advisers's portfolio value rose 9.3% quarter-over-quarter to $59.8B.
Based on RhumbLine Advisers's 13F filing for Q4 2019, filed 5 Feb 2020.